Biotheryx, Inc. revealed that their Investigational New Drug application for BTX-9341, an innovative bifunctional degrader targeting cyclin-dependent kinase 4/6 (CDK4/6).

Axicabtagene ciloleucel, branded as Yescarta, is a revolutionary immunotherapy medication developed by Kite Pharma, a subsidiary of Gilead Sciences.

CMG901 (AZD0901) is a potentially first-in-class antibody-drug conjugate targeting Claudin 18.2, conjugated with monomethyl auristatin E (MMAE) as the payload.

A dose escalation trial, also known as a dose-ranging study, is a type of clinical trial design used primarily in Phase I of drug development.

Neurogene revealed promising safety results from its Phase 1/2 study on NGN-401, a gene therapy for Rett Syndrome.

Mometasone topical, commercially known as Elocon, is a potent corticosteroid medication developed by Novartis Pharmaceuticals Corporation.

May 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Seamless Phase I/II clinical trials are a type of clinical trial design that combines elements of both Phase I and Phase II trials into a single study.

Merus Reveals FDA Approval and Expedited Assessment of BLA for Zeno to Manage NRG1+ Lung and Pancreatic Cancer.

Canagliflozin, marketed under the brand name Invokana, is a medication developed by Janssen Pharmaceuticals, a division of Johnson & Johnson, for the treatment of type 2 diabetes mellitus.

Positive Phase 2 Results for XyloCor Therapeutics’ Main Candidate XC001 Announced at SCAI 2024 and in the Journal Circulation: Cardiovascular Interventions.

At the upcoming ASCO conference, Mabwell (Shanghai) Bioscience will present the Phase I/II clinical study results of 9MW2821 for several advanced solid tumors through an oral report.